DK175903B1 - Ikke-solvatiseret krystallinsk form af 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid - Google Patents

Ikke-solvatiseret krystallinsk form af 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid Download PDF

Info

Publication number
DK175903B1
DK175903B1 DK199501027A DK102795A DK175903B1 DK 175903 B1 DK175903 B1 DK 175903B1 DK 199501027 A DK199501027 A DK 199501027A DK 102795 A DK102795 A DK 102795A DK 175903 B1 DK175903 B1 DK 175903B1
Authority
DK
Denmark
Prior art keywords
hydroxy
benzo
benzoyl
piperidinoethoxy
reaction
Prior art date
Application number
DK199501027A
Other languages
Danish (da)
English (en)
Other versions
DK102795A (da
Inventor
Elizabeth Smith Labell
Wayne Douglas Luke
Randal Scot Miller
Mcneill Mcgill John Iii
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK175903(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK102795A publication Critical patent/DK102795A/da
Application granted granted Critical
Publication of DK175903B1 publication Critical patent/DK175903B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK199501027A 1994-09-19 1995-09-15 Ikke-solvatiseret krystallinsk form af 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid DK175903B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US30832594 1994-09-19
US42791495A 1995-04-26 1995-04-26
US42791495 1995-04-26

Publications (2)

Publication Number Publication Date
DK102795A DK102795A (da) 1996-03-20
DK175903B1 true DK175903B1 (da) 2005-06-06

Family

ID=26976194

Family Applications (4)

Application Number Title Priority Date Filing Date
DK199501028A DK175897B1 (da) 1994-09-19 1995-09-15 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid og krystallinske solvater heraf til brug ved fremgangsmåden
DK199501027A DK175903B1 (da) 1994-09-19 1995-09-15 Ikke-solvatiseret krystallinsk form af 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid
DK199700028A DK175886B1 (da) 1994-09-19 1997-01-09 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid
DK199700027A DK175887B1 (da) 1994-09-19 1997-01-09 Fremgangsmåde til fremstilling af krystallinske solvater af 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo(b)thiophener

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK199501028A DK175897B1 (da) 1994-09-19 1995-09-15 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid og krystallinske solvater heraf til brug ved fremgangsmåden

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK199700028A DK175886B1 (da) 1994-09-19 1997-01-09 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid
DK199700027A DK175887B1 (da) 1994-09-19 1997-01-09 Fremgangsmåde til fremstilling af krystallinske solvater af 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo(b)thiophener

Country Status (51)

Country Link
US (4) US5731327A (ko)
JP (2) JPH08193081A (ko)
KR (2) KR100381346B1 (ko)
CN (2) CN1068324C (ko)
AP (1) AP754A (ko)
AT (2) AT407988B (ko)
AU (3) AU691955B2 (ko)
BE (2) BE1009625A3 (ko)
BG (1) BG62793B1 (ko)
BR (2) BR9504060A (ko)
CA (2) CA2158399C (ko)
CH (3) CH691594A5 (ko)
CO (2) CO4410191A1 (ko)
CZ (2) CZ290343B6 (ko)
DE (3) DE19534744A1 (ko)
DK (4) DK175897B1 (ko)
EE (1) EE03386B1 (ko)
EG (1) EG23763A (ko)
ES (2) ES2109882B1 (ko)
FI (2) FI112226B (ko)
FR (2) FR2732020B1 (ko)
GB (2) GB2293382B (ko)
GE (1) GEP19991821B (ko)
GR (2) GR1002697B (ko)
HK (1) HK1019009A1 (ko)
HR (2) HRP950483B1 (ko)
HU (2) HU227683B1 (ko)
IE (2) IE950722A1 (ko)
IL (3) IL115315A (ko)
IS (1) IS1788B (ko)
IT (2) IT1277601B1 (ko)
LU (2) LU88660A1 (ko)
LV (2) LV11177B (ko)
MY (1) MY116371A (ko)
NL (2) NL1001196C2 (ko)
NO (2) NO313996B1 (ko)
NZ (2) NZ280028A (ko)
OA (1) OA10406A (ko)
PE (2) PE14796A1 (ko)
PL (2) PL182450B1 (ko)
PT (2) PT101771B (ko)
RO (2) RO115259B1 (ko)
RS (2) RS49578B (ko)
SE (2) SE520721C2 (ko)
SI (2) SI9500293A (ko)
SK (1) SK283502B6 (ko)
TR (1) TR199501136A2 (ko)
TW (1) TW412534B (ko)
UA (2) UA42716C2 (ko)
UY (1) UY24040A1 (ko)
WO (1) WO1996009045A1 (ko)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410191A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
ME00074B (me) * 1996-03-26 2010-10-10 Lilly Co Eli Benzotiofeni, formulacije koje ih sadrže i proizvod
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
RU2203060C2 (ru) 1996-10-30 2003-04-27 Эли Лилли Энд Компани Способ профилактики рака молочной железы
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
AU2002230409A1 (en) * 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003266940B2 (en) 2002-09-30 2007-02-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1797038B1 (en) 2004-09-29 2012-06-13 Bayer Pharma Aktiengesellschaft Thermodynamically stable form of bay 43-9006 tosylate
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2007128721A1 (de) 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphe
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8344149B2 (en) * 2006-10-17 2013-01-01 Cipla Limited Crystalline form of benzothiophene compound and process for preparation thereof
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
WO2009015004A1 (en) * 2007-07-20 2009-01-29 King Pharmaceuticals Research And Development, Inc. Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2307399B1 (en) * 2008-06-09 2016-05-18 ERREGIERRE S.p.A. Process for controlling the growth of a raloxifene hydrochloride crystal
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2448562B1 (en) 2009-07-02 2013-11-06 Synthon B.V. Raloxifene composition
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
IN2013MU00665A (ko) 2013-03-05 2015-07-03 Cipla Ltd
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
GB2097788B (en) 1981-04-03 1985-04-24 Lilly Co Eli Benzothiophene compounds and process for preparing them
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
IL110052A (en) 1993-06-24 2001-04-30 Lilly Co Eli Pharmaceutical preparations containing derivatives of benzothiophene used as hypoglycemic compounds
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410191A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS

Also Published As

Publication number Publication date
UA42716C2 (uk) 2001-11-15
LV11178B (en) 1996-08-20
KR960010634A (ko) 1996-04-20
SI9500292A (en) 1996-06-30
CA2158399A1 (en) 1996-03-20
NL1001194A1 (nl) 1996-03-19
ES2129293B1 (es) 2000-01-16
US6472531B1 (en) 2002-10-29
FI121424B (fi) 2010-11-15
TW412534B (en) 2000-11-21
OA10406A (en) 2001-12-05
CZ292007B6 (cs) 2003-07-16
IL115314A0 (en) 1996-05-14
PE14796A1 (es) 1996-05-19
AT502957A1 (de) 2007-06-15
BG101242A (en) 1998-03-31
GB9519028D0 (en) 1995-11-15
HRP950483A2 (en) 1997-10-31
BR9504060A (pt) 1996-09-24
BE1009625A3 (fr) 1997-06-03
SI9500293A (en) 1996-06-30
CA2158400A1 (en) 1996-03-20
ITMI951936A0 (it) 1995-09-15
GB2293602B (en) 1998-05-06
WO1996009045A1 (en) 1996-03-28
FI954403A (fi) 1996-03-20
CH691594A5 (de) 2001-08-31
RO115259B1 (ro) 1999-12-30
PT101770B (pt) 1997-04-30
UY24040A1 (es) 1996-03-07
CZ240295A3 (en) 1996-04-17
FR2732020A1 (fr) 1996-09-27
CZ290343B6 (cs) 2002-07-17
EE9700055A (et) 1997-08-15
YU61495A (sh) 1998-05-15
IL125283A (en) 2001-06-14
UA44240C2 (uk) 2002-02-15
GB2293382B (en) 1998-08-19
AU692907B2 (en) 1998-06-18
IT1277602B1 (it) 1997-11-11
SK283502B6 (sk) 2003-08-05
US20020173645A1 (en) 2002-11-21
NZ280027A (en) 1997-05-26
FR2732020B1 (fr) 1997-11-14
CN1127253A (zh) 1996-07-24
GEP19991821B (en) 1999-11-05
NL1001194C2 (nl) 1997-04-04
DK175897B1 (da) 2005-05-30
NL1001196C2 (nl) 1997-04-04
HK1019009A1 (en) 2000-01-14
PL182450B1 (pl) 2002-01-31
DK102795A (da) 1996-03-20
HU227683B1 (en) 2011-11-28
SE9503214L (sv) 1996-03-20
KR100367376B1 (ko) 2003-03-06
NO313996B1 (no) 2003-01-13
TR199501136A2 (tr) 1996-06-21
PT101771A (pt) 1996-04-30
DK175887B1 (da) 2005-05-23
NO953658D0 (no) 1995-09-15
SE9503213D0 (sv) 1995-09-15
NO953658L (no) 1996-03-20
PT101770A (pt) 1996-04-30
AT407988B (de) 2001-07-25
SE520721C2 (sv) 2003-08-12
US5731327A (en) 1998-03-24
RS49513B (sr) 2006-10-27
RO115260B1 (ro) 1999-12-30
EG23763A (en) 2007-08-08
IS1788B (is) 2001-11-28
LU88660A1 (fr) 1996-07-15
FI954402A (fi) 1996-03-20
SE9503214D0 (sv) 1995-09-15
CZ240395A3 (en) 1996-04-17
IL115315A (en) 1999-09-22
DK2797A (da) 1997-01-09
FI954403A0 (fi) 1995-09-18
ITMI951935A1 (it) 1997-03-15
FR2724655A1 (fr) 1996-03-22
MY116371A (en) 2004-01-31
CA2158400C (en) 2006-10-24
AU3173195A (en) 1996-04-04
HRP950482B1 (en) 2007-04-30
IT1277601B1 (it) 1997-11-11
ITMI951936A1 (it) 1997-03-15
ES2129293A1 (es) 1999-06-01
BE1009626A3 (fr) 1997-06-03
IL115314A (en) 2000-02-29
IE950722A1 (en) 1996-03-20
AU3173095A (en) 1996-04-04
DE19534745B4 (de) 2004-06-09
DE19534745A1 (de) 1996-04-04
DE19534744A1 (de) 1996-03-21
NO953657L (no) 1996-03-20
SE9503213L (sv) 1996-03-20
FI954402A0 (fi) 1995-09-18
CH691125A5 (de) 2001-04-30
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
HU9502723D0 (en) 1995-11-28
LV11178A (lv) 1996-04-20
ES2109882B1 (es) 1998-08-16
IL115315A0 (en) 1995-12-31
NO953657D0 (no) 1995-09-15
LU88661A1 (fr) 1996-07-15
HRP950482A2 (en) 1998-02-28
BG62793B1 (bg) 2000-08-31
US6399778B1 (en) 2002-06-04
HU9502721D0 (en) 1995-11-28
LV11177B (en) 1996-08-20
DK175886B1 (da) 2005-05-23
BR9504059A (pt) 1996-09-24
GR1002697B (el) 1997-05-22
RS49578B (sr) 2007-04-10
NO308107B1 (no) 2000-07-24
JPH08176147A (ja) 1996-07-09
LV11177A (lv) 1996-04-20
GR1002709B (el) 1997-06-04
FI112226B (fi) 2003-11-14
IE80883B1 (en) 1999-05-19
HRP950483B1 (en) 2003-02-28
HUT75033A (en) 1997-03-28
PL310517A1 (en) 1996-04-01
YU61395A (sh) 1998-09-18
CN1075069C (zh) 2001-11-21
EE03386B1 (et) 2001-04-16
HUT74178A (en) 1996-11-28
DK2897A (da) 1997-01-09
NL1001196A1 (nl) 1996-03-19
KR960010637A (ko) 1996-04-20
AU691955B2 (en) 1998-05-28
GB2293602A (en) 1996-04-03
KR100381346B1 (ko) 2004-04-13
CH691478A5 (de) 2001-07-31
CO4410190A1 (es) 1997-01-09
ES2109882A1 (es) 1998-01-16
SK23397A3 (en) 1997-08-06
FR2724655B1 (fr) 1997-11-14
JP2860071B2 (ja) 1999-02-24
DK102895A (da) 1996-03-20
CN1068324C (zh) 2001-07-11
GB2293382A (en) 1996-03-27
CO4410191A1 (es) 1997-01-09
ITMI951935A0 (it) 1995-09-15
PT101771B (pt) 1997-04-30
SE509265C2 (sv) 1998-12-21
CN1132205A (zh) 1996-10-02
GB9519032D0 (en) 1995-11-15
PL187686B1 (pl) 2004-09-30
AP9700938A0 (en) 1997-04-30
PE32796A1 (es) 1996-08-07
IE950721A1 (en) 1996-03-20
ATA154295A (de) 2000-12-15
AP754A (en) 1999-07-22
PL310518A1 (en) 1996-04-01
JPH08193081A (ja) 1996-07-30
DE19549755B4 (de) 2005-05-04
NZ280028A (en) 1997-05-26
IS4446A (is) 1997-03-18
HU225417B1 (en) 2006-11-28

Similar Documents

Publication Publication Date Title
DK175903B1 (da) Ikke-solvatiseret krystallinsk form af 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid
RU2108331C1 (ru) Способ получения кристаллического сольвата, кристаллический сольват 6-гидрокси-2-(4-гидроксифенил)-3-[4-(2-пиперидиноэтокси)бензоил]бензо(b)тиофенгидрохлорида и способ получения несольватированного кристаллического 6-гидрокси-2-(4-гидроксифенил)-3-[4-(2-пиперидиноэтокси)бензоил]бензо(b)тиофенгидрохлорида

Legal Events

Date Code Title Description
PBP Patent lapsed

Effective date: 20140930